Cargando…

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

BACKGROUND: The lipid-lowering and positive cardiovascular effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are more widely used in the lipid-lowering management of individuals with high cardiovascular risk. As real-world data are s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer, Laurenz T., Hochfellner, Daniel A., Knoll, Lisa, Pöttler, Tina, Mader, Julia K., Aberer, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070307/ https://www.ncbi.nlm.nih.gov/pubmed/33894772 http://dx.doi.org/10.1186/s12933-021-01283-w

Ejemplares similares

Application of Telemedicine in Diabetes Care: The Time is Now
por: Aberer, Felix, et al.
Publicado: (2021)

Real-world use of PCSK9 inhibitors: A single-center experience
por: Sarsam, Sinan, et al.
Publicado: (2018)

A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital
por: Aberer, Felix, et al.
Publicado: (2021)

Accuracy Assessment of the GlucoMen(®) Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study
por: Hochfellner, Daniel A., et al.
Publicado: (2022)

Reply to Freckmann et al. Comment on “Hochfellner et al. Accuracy Assessment of the GlucoMen(®) Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study. Biosensors 2022, 12, 106”
por: Hochfellner, Daniel A., et al.
Publicado: (2023)

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Wang, Yu, et al.
Publicado: (2016)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
por: Blanco-Ruiz, Marina, et al.
Publicado: (2021)

A Genetic Approach to the Association Between PCSK9 and Sepsis
por: Feng, QiPing, et al.
Publicado: (2019)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Medication errors in type 2 diabetes from patients’ perspective
por: Mader, Julia K., et al.
Publicado: (2022)

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
por: Chamberlain, Alanna M., et al.
Publicado: (2019)

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
por: Uno-Eder, Kiyoko
Publicado: (2023)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
por: Girona, Josefa, et al.
Publicado: (2016)

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
por: Caselli, Chiara, et al.
Publicado: (2019)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
por: Lu, Fengyuan, et al.
Publicado: (2023)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
por: Peng, Jia, et al.
Publicado: (2020)

Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance
por: Macchi, C., et al.
Publicado: (2020)

Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
por: Lin, Po-Lin, et al.
Publicado: (2023)

People with type 1 diabetes and impaired awareness of hypoglycaemia have a delayed reaction to performing a glucose scan during hypoglycaemia: a prospective observational study
por: Moser, O., et al.
Publicado: (2020)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks
por: Hollstein, Tim, et al.
Publicado: (2020)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

Protein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies (PCSK9mab) in Clinical Practice at Secondary Care – Real World Multicentre Experience
por: Bashir, Bilal, et al.
Publicado: (2022)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
por: Warden, Bruce A., et al.
Publicado: (2020)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study
por: Seijas-Amigo, Jose, et al.
Publicado: (2023)

Real-World Analysis of Therapeutic Outcome in Type 1 Diabetes Mellitus at a Tertiary Care Center
por: Kietaibl, Antonia, et al.
Publicado: (2022)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nbcui5l66gln9h7slev8u7mgk7